Vanguard Group Inc. lifted its stake in Glaukos Co. (NYSE:GKOS - Free Report) by 1.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 5,974,971 shares of the medical instruments supplier's stock after purchasing an additional 101,838 shares during the period. Vanguard Group Inc. owned approximately 10.84% of Glaukos worth $895,887,000 as of its most recent SEC filing.
A number of other institutional investors have also recently added to or reduced their stakes in the stock. IFP Advisors Inc purchased a new position in Glaukos in the fourth quarter valued at about $43,000. Asset Planning Inc purchased a new position in Glaukos in the 4th quarter valued at approximately $90,000. Picton Mahoney Asset Management purchased a new position in Glaukos in the 4th quarter valued at approximately $125,000. SBI Securities Co. Ltd. acquired a new position in Glaukos during the fourth quarter worth $153,000. Finally, Smartleaf Asset Management LLC boosted its position in Glaukos by 275.4% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,100 shares of the medical instruments supplier's stock worth $164,000 after purchasing an additional 807 shares in the last quarter. Hedge funds and other institutional investors own 99.04% of the company's stock.
Analysts Set New Price Targets
A number of research analysts have recently weighed in on GKOS shares. Truist Financial raised their price target on Glaukos from $152.00 to $185.00 and gave the company a "buy" rating in a research report on Wednesday, December 18th. Citigroup upgraded shares of Glaukos from a "neutral" rating to a "buy" rating and lifted their target price for the stock from $132.00 to $162.00 in a research report on Wednesday, December 11th. UBS Group began coverage on shares of Glaukos in a research report on Friday, December 6th. They issued a "buy" rating and a $182.00 price target on the stock. Mizuho upgraded Glaukos from a "neutral" rating to an "outperform" rating and lifted their price objective for the stock from $140.00 to $200.00 in a research report on Wednesday, February 19th. Finally, Stifel Nicolaus upped their target price on Glaukos from $153.00 to $175.00 and gave the company a "buy" rating in a research note on Tuesday, December 31st. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $163.25.
View Our Latest Stock Analysis on GKOS
Glaukos Trading Up 0.7 %
Shares of GKOS stock traded up $0.68 during mid-day trading on Wednesday, hitting $97.77. 155,119 shares of the company's stock were exchanged, compared to its average volume of 605,335. The stock has a market cap of $5.53 billion, a price-to-earnings ratio of -34.06 and a beta of 0.99. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19. Glaukos Co. has a fifty-two week low of $88.16 and a fifty-two week high of $163.71. The stock has a 50-day simple moving average of $128.12 and a two-hundred day simple moving average of $135.38.
Glaukos (NYSE:GKOS - Get Free Report) last issued its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.02). The business had revenue of $105.50 million during the quarter, compared to analyst estimates of $100.72 million. Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. Equities analysts expect that Glaukos Co. will post -1.08 EPS for the current fiscal year.
Insider Buying and Selling
In other news, insider Tomas Navratil sold 3,416 shares of the firm's stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $147.14, for a total value of $502,630.24. Following the transaction, the insider now directly owns 72,437 shares in the company, valued at $10,658,380.18. This trade represents a 4.50 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Alex R. Thurman sold 1,520 shares of the business's stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $106.84, for a total value of $162,396.80. Following the sale, the chief financial officer now owns 53,431 shares of the company's stock, valued at $5,708,568.04. The trade was a 2.77 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 6.40% of the company's stock.
About Glaukos
(
Free Report)
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.
See Also
Before you consider Glaukos, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Glaukos wasn't on the list.
While Glaukos currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
